Endpoints News

What's at stake at ESC		Read in browser

Thank you for reading, dupa dupackia!

basic

UPGRADE

M Tue W Th F

25 August, 2026

One night, one room: the founders, scientists and investors behind the Endpoints 11, together in Boston this September. Reserve your spot now and save with the early bird rate.

news

Exclusive: Bausch + Lomb plans Phase 3 trial for dry eye drop, despite missing mid-stage goal

DC judge rejects Merck’s IRA case more than three years after it was filed

News on AstraZeneca, Cytokinetics, Novartis and more — what to look out for at ESC 2026

Aug 27

12:00 pm ET

Same molecule, different paths: Where value goes in cross-border dealmaking in a new era

in case you missed it

Capricor's Duchenne cell therapy gets PDUFA date extended as FDA reviews new data

Regenxbio hit with another clinical hold for Hunter syndrome gene therapy

Option-to-acquire deals remain rare in biotech's buzzy M&A season

Roche bets up to $2.3B on Hanmi’s early-stage muscle-building obesity asset

News Briefing

TwinStrand wins patent case; GSK’s hepatitis B drug approved in Japan

Roche, Eli Lilly's Alzheimer's blood test gets FDA clearance

Patient’s own mitochondria injected into eyes in attempt to restore vision

Elizabeth Cairns will be in Munich to cover this year's ESC Congress, so stay tuned for our reporting over the coming days. We're also keeping a close eye on the European Respiratory Society meeting in early September. If you have news to share, reach out to Ayisha Sharma.

Reynald Castaneda

Deputy Editor, Endpoints News

2029 Becker Drive; Lawrence, Kansas 66047 USA Privacy and deletion: help@endpointsnews.com